ASCO 2022: ADCs at a glance…
- Of the 117 ADC-relevant abstracts presented at ASCO 2022, 47% describe data for investigating approved ADCs.
- Five late-stage studies of four unapproved traditional ADCs were presented.
- The race to formulate an effective HER2-positive breast cancer treatment has taken hold of the ADC community with KADCYLA® and ENHERTU® being the most discussed ADCs.
- Given the success of ENHERTU® in HER2-low breast cancer treatment, ADCs may represent the future of HER2-targeted therapies in patients with low HER2 expression.
For more detail, data, and insight please download our infographic.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements